Form 4: KalVista Pharmaceuticals Chief Medical Officer Sells Shares to Cover Tax Obligations

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, sold 2,187 shares to cover tax obligations related to the vesting of restricted stock units.

Summary

• Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, engaged in transactions involving the company's common stock.
• On November 22, 2024, 5,000 restricted stock units (RSUs) vested, each representing a contingent right to receive one share of common stock.
• To cover tax withholding obligations associated with the vesting of these RSUs, Mr. Audhya sold 2,187 shares on November 26, 2024, at a weighted average price of $9.8702 per share.
• The sale was not a discretionary transaction but rather a 'sell to cover' transaction to satisfy tax obligations.
• Following these transactions, Mr. Audhya beneficially owns 97,012 shares of KalVista Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for company executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• The sale of shares to cover tax obligations is a standard practice among executives in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• Many companies use restricted stock units as part of their compensation packages, and the vesting of these units often triggers tax liabilities for the recipients.
• Similar transactions are regularly reported by executives at comparable companies such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally considered a routine transaction.
• The transaction does not have a significant impact on the company's operations or financial health.

Key Dates

Keywords

KalVista Pharmaceuticals, insider trading, Form 4, restricted stock units, tax obligations, share sale, Paul K. Audhya, Chief Medical Officer